Exeter Handkerchief Factory hits market at $3.5M
A vestige of Exeter’s industrial past in the historic Lincoln Street corridor is up for sale, and it has a hefty price tag.
Sections
Extras
Connect With Us

What’s being described as the last large auto site in Concord, at 94 Manchester St., has been purchased for $1.8 million by Key Auto Group. Seller was W&E Realty LLC.
According to Doug Martin of Colliers International, the 11-acre mixed-use lot was the last large auto sale site in Concord. He said the buyer plans to redevelop the site into a full-service Key Auto Group location, including relocating Key Collision of Concord to a new 20,000-square-foot facility on the site. The property adds to Key’s growing portfolio in New Hampshire, said Martin.
Martin, of Colliers’ Manchester office, represented the seller and assisted the buyer in the transaction.
A vestige of Exeter’s industrial past in the historic Lincoln Street corridor is up for sale, and it has a hefty price tag.
Real estate transactions in New Hampshire invariably carry tax consequences. Whether you are a business owner, investor, or advisor, thoughtful tax planning is critical to preserving value and avoiding costly missteps.
Since 2020, our research team at the University of New Hampshire — the New Hampshire Youth Retention Initiative (YRI) — has been studying how young people view the Granite State as a place to live, learn and work.
The people of New Hampshire are facing unprecedented economic challenges — no one has been spared from rising grocery bills, increased rent and utility costs, and even higher car insurance premiums.
When I started my first business in 1982, I didn’t know exactly where the journey would lead. What I did know was that I wanted to build something lasting, something rooted in innovation and capable of creating good jobs.
Business and event happenings around the state of NH
The Latest is a roundup of the comings and goings of the movers and shakers in NH's business community
Reform bill cosponsored by U.S. Sen. Maggie Hassan would break the link between PBM compensation and drug prices